|
|
Post by lakers on Feb 19, 2016 2:03:35 GMT -5
7th Annual Drug Delivery & Formulation Summit May 23 - 25 2016 Berlin Germany Credit to Kevinmik STREAM 3 technology & partnerships EXPLORING INHALED DRUG DELIVERY FORMULATIONS www.ddfevent.com/programme/Analysing inhalation technology for pulmonary drug delivery Using exemplifying inhalation technology for the treatment of pain Applying ultra-rapid drug delivery technology by incorporating Technosphere dry power formulations Using powder inhalation with small, breath-powders by applying pre-metered single use cartridges Philippe Rogueda Monash University Adjunct Senior Lecturer UK FDA Phase I:GSK Study of Oxytocin (GR121619) Via an Inhaled Alternative Names: GR-121619; Research programme: heat-stable oxytocin - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences Read more: mnkd.proboards.com/thread/3964/phase-study-oxytocin-gr121619-inhaled#ixzz40azM9mfBAn Innovative Route to Inhaled Product Industrialisation: The Monash-GSK Australia Partnership Philip Leslie – Site Technical Lead GSK Australia David Morton – Monash Institute of Pharmaceutical Science ddl-conference.com/files2/SpeakerPresentationsDDL23/Friday7th/2.Morton.pdf |
|
|
|
Post by yash on Feb 19, 2016 3:43:30 GMT -5
Good find. Thanks to Lakers and Kevin.
|
|
|
|
Post by fofos2000i on Feb 19, 2016 4:49:50 GMT -5
|
|
|
|
Post by lakers on Feb 19, 2016 19:42:55 GMT -5
Philippe Rogueda Executive Director at Aedestra Ltd Hong KongPharmaceuticals Current Aedestra Ltd, Inhalation Asia Previous Cambridge IP, VaryDose, Monash University Education London Business School Executive Director Aedestra Ltd October 2014 – Present (1 year 5 months)Hong Kong Aedestra Ltd is an inhalation R&D company providing services to pharmaceutical companies wishing to develop and register OINDPs in EU, US, Asian and LATAM markets. • Provide formulation, device, clinical, filing and regulatory affairs decision making support across new and existing inhalation technologies including dry powder and soft mist inhalers. • Management of filings in multiple territories to drive expansion into the Latin American, EU, US and Canadian markets. • Provide strategic support to a R&D laboratories including troubleshooting and defining / implementing process improvements; successfully resolved DPI inhaler formulation issues. • Support clients in patent court hearings, with inhalation portfolio strategy and choices, and regulatory filings. Keywords: Inhaled drug delivery, OINDP, Inhaler, pMDI, DPI, Nebules, Nasal, Softmist, Inhalation, Aerosol, Business Development, P&L analysis, Portfolio selection, Clinical trials, Regulatory submission, Devices, Project management, China, EU, US Co-founder and Director Inhalation Asia November 2012 – Present (3 years 4 months)Hong Kong Scientific Board Member Cambridge IP January 2012 – December 2015 (4 years)Cambridge, United Kingdom Chief Technology Officer VaryDose November 2011 – December 2015 (4 years 2 months)London, United Kingdom Adjunct Senior Lecturer
Monash University
September 2006 – December 2014 (8 years 4 months)
Director Inhalation R&D Chemo September 2014 – October 2014 (2 months)Las Tablas, Madrid - Azuqueca de Henares Executive Director - Emerging Technologies Actavis March 2012 – August 2014 (2 years 6 months)London, UK Visiting Professor Kunming University of Science and Technology October 2011 – October 2013 (2 years 1 month)Kunming, Yunan, China Principal Fellow Novartis October 2007 – October 2011 (4 years 1 month)Horsham, Sussex |
|
|
|
Post by mindovermatter on Feb 19, 2016 20:15:34 GMT -5
Sorry to pour cold water on this thread but if you do a simple search for oxytocin and mannkind you'll come up with this as the first hit. www.mintakafoundation.org/our-projects/maternal-health/If I remember correctly, Matt spoke about this several months ago. Also doing a search on here brings up an older thread that dispels Monash as the company. With all the research Lakers does, you'd think he would have figured out there is no link between Mannkind and Monash with Oxytocin especially when I just figured it out in less than 10 seconds typing it into google. The fact is it is another nonprofit that happens to have M as the first letter of its name. |
|
|
|
Post by lakers on Feb 19, 2016 20:50:50 GMT -5
Sorry to pour cold water on this thread but if you do a simple search for oxytocin and mannkind you'll come up with this as the first hit. www.mintakafoundation.org/our-projects/maternal-health/If I remember correctly, Matt spoke about this several months ago. Also doing a search on here brings up an older thread that dispels Monash as the company. With all the research Lakers does, you'd think he would have figured out there is no link between Mannkind and Monash with Oxytocin especially when I just figured it out in less than 10 seconds typing it into google. The fact is it is another nonprofit that happens to have M as the first letter of its name. You miss the point. Monash uses TS for pain med. That's new. Monash has been doing research for GSK. Oxytocin was one example. |
|
|
|
Post by mindovermatter on Feb 20, 2016 8:40:32 GMT -5
Sorry to pour cold water on this thread but if you do a simple search for oxytocin and mannkind you'll come up with this as the first hit. www.mintakafoundation.org/our-projects/maternal-health/If I remember correctly, Matt spoke about this several months ago. Also doing a search on here brings up an older thread that dispels Monash as the company. With all the research Lakers does, you'd think he would have figured out there is no link between Mannkind and Monash with Oxytocin especially when I just figured it out in less than 10 seconds typing it into google. The fact is it is another nonprofit that happens to have M as the first letter of its name. You miss the point. Monash uses TS for pain med. That's new. Monash has been doing research for GSK. Oxytocin was one example. I have looked over your post and see no evidence of this other than you assuming it. Monash has been using Nektar's technology starting with the Oxytocin. What that leads me to believe is they are using that same inahlation technology for other uses. Unlike Mintaka that actually states the fact they had help from Mannkind, Monash states nothing about Mannkind at all. I think you are making the wrong conclusion using absolutely no facts but relying on key words to fit your narrative. But this wouldn't be the first time you have done so. |
|
|
|
Post by suebeeee1 on Feb 20, 2016 15:48:21 GMT -5
mindovermatter, let's all try and play nice in the sandbox. This is the actual session listed at the drug delivery conference of which Lakers referenced: STREAM 3 technology & partnerships EXPLORING INHALED DRUG DELIVERY FORMULATIONS Analysing inhalation technology for pulmonary drug delivery Using exemplifying inhalation technology for the treatment of pain Applying ultra-rapid drug delivery technology by incorporating Technosphere dry power formulations Using powder inhalation with small, breath-powders by applying pre-metered single use cartridges Philippe Rogueda Monash University Adjunct Senior Lecturer UK Notice, it specifically references "Technosphere". And, unless that term is not copywrited in Germany (and we know it is), it appears that Philippe Rogueda from Monash is involved with Mannkind.
|
|
|
|
Post by peppy on Feb 20, 2016 15:59:02 GMT -5
mindovermatter , let's all try and play nice in the sandbox. This is the actual session listed at the drug delivery conference of which Lakers referenced: STREAM 3 technology & partnerships EXPLORING INHALED DRUG DELIVERY FORMULATIONS Analysing inhalation technology for pulmonary drug delivery Using exemplifying inhalation technology for the treatment of pain Applying ultra-rapid drug delivery technology by incorporating Technosphere dry power formulations Using powder inhalation with small, breath-powders by applying pre-metered single use cartridges Philippe Rogueda Monash University Adjunct Senior Lecturer UK Notice, it specifically references "Technosphere". And, unless that term is not copywrited in Germany (and we know it is), it appears that Philippe Rogueda from Monash is involved with Mannkind. A few months back, remember the patent for the new inhaler? Was that a GSK patent? it was a technosphere inhaler. Mn and all do you remember? (The inhaler seemed to have an added gauge. For dose control?)
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 20, 2016 16:40:06 GMT -5
Are any of MNKD management connected through linked in to people from this company?
|
|
|
|
Post by peppy on Feb 20, 2016 17:15:21 GMT -5
mindovermatter , let's all try and play nice in the sandbox. This is the actual session listed at the drug delivery conference of which Lakers referenced: STREAM 3 technology & partnerships EXPLORING INHALED DRUG DELIVERY FORMULATIONS Analysing inhalation technology for pulmonary drug delivery Using exemplifying inhalation technology for the treatment of pain Applying ultra-rapid drug delivery technology by incorporating Technosphere dry power formulations Using powder inhalation with small, breath-powders by applying pre-metered single use cartridges Philippe Rogueda Monash University Adjunct Senior Lecturer UK Notice, it specifically references "Technosphere". And, unless that term is not copywrited in Germany (and we know it is), it appears that Philippe Rogueda from Monash is involved with Mannkind. A few months back, remember the patent for the new inhaler? Was that a GSK patent? it was a technosphere inhaler. Mn and all do you remember? (The inhaler seemed to have an added gauge. For dose control?)
here is the link to the inhaler mnkd.proboards.com/thread/3166/mannkind-inhalation-simulation-system-patented
|
|
